Former President and Chief Executive Officer; Executive Chairman · AGIOS PHARMACEUTICALS, INC. (AGIO)

David Schenkein

A named executive officer of AGIOS PHARMACEUTICALS in every fiscal year CompBrief holds from FY2016 to FY2019. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$2,576,376

Salary $212,500Stock awards $489,951

FY2018: $8,199,324

5th of 5 named executive officers at Agios Pharmaceuticals by FY2019 total.

5 named officers on file for AGIOS PHARMACEUTICALS, FY2019

David Schenkein’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 4 equity grants, each cited to its filing
  • AGIO’s disclosed peer group of 14 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how AGIOS PHARMACEUTICALS’s whole pay program stands against its peers

  • AGIOS PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on AGIO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 16, 2020 (DEF 14A).

Free

Get David Schenkein’s full pay file as a PDF — free

More than this page: up to 10 years of David’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

David Schenkein compensation by year

AGIOS PHARMACEUTICALS Summary Compensation Table · all 4 fiscal years held
In US dollars, as AGIOS PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019
Salary$568,000$585,040$625,000$212,500
Bonus$0$0$0$0
Stock awards$0$0$1,893,938$489,951
Option awards$2,582,051$4,921,476$5,160,125$1,840,179
Non-equity incentive$340,800$456,300$507,813$30,469
Pension and deferred compensation$0$0$0$0
All other$9,928$9,548$12,448$3,277
Total$3,500,779$5,972,364$8,199,324$2,576,376

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: AGIOS PHARMACEUTICALS, INC. DEF 14A filed April 16, 2020, accession 0001193125-20-109284, and prior-year filings. Open the filing on EDGAR.

How this page was built: the AGIOS PHARMACEUTICALS, INC. filed document, accession 0001193125-20-109284. Every figure is read from that document and cited to the page and table it appears in. Filed April 16, 2020.

$3.5M
$6.0M
$8.2M
$2.6M
FY16
FY17
FY18
FY19
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2019 year-end
TypeUnvested unitsValue at year-endExercise price
RSU16,250$775,938—
RSU8,324$397,471—
Option41,681—$50.40
Option52,815—$77.70
Option45,719—$58.86
Option4,250—$39.76

Per the Outstanding Equity Awards at Fiscal Year-End table in AGIOS PHARMACEUTICALS, INC.'s FY2019 proxy; value at the fiscal year-end close, as the company printed it.

AGIOS PHARMACEUTICALS’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
Jacqualyn FouseChief Executive Officer$16,607,994
Andrew HirschFormer Chief Financial Officer$4,248,831
Christopher BowdenFormer Chief Medical Officer$3,227,208
Jonathan BillerChief Legal Officer$3,183,889
David Schenkein · this pageFormer President and Chief Executive Officer; Executive Chairman$2,576,376

Board service

AGIOS PHARMACEUTICALS board · FY2021–FY2025
Director compensation in US dollars, as AGIOS PHARMACEUTICALS reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$9,424$0$0$0$9,424
FY2024$57,500$89,994$266,287$0$413,781
FY2023$57,500$89,985$269,767$0$417,252
FY2022$72,500$89,997$269,800$0$432,297
FY2021$87,500$89,965$269,983$0$447,447

Each year as the company reported it in AGIOS PHARMACEUTICALS's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: AGIOS PHARMACEUTICALS pays directors a $50,000 cash retainer and $400,000 in RSUs/Options. As stated in AGIOS PHARMACEUTICALS's FY2025 proxy.

The full AGIOS PHARMACEUTICALS compensation record

free company brief

This page is one person within AGIOS PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are AGIOS PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

David Schenkein's compensation dossier · One-time report. No refunds.